178 related articles for article (PubMed ID: 34035415)
81. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
82. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
83. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
84. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
Front Immunol; 2021; 12():667875. PubMed ID: 34603277
[TBL] [Abstract][Full Text] [Related]
85. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS; Aguiar P; Haaland B; Lopes G
Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
[TBL] [Abstract][Full Text] [Related]
86. Microwave ablation of non-small cell lung cancer tumors changes plasma levels of cytokines IL-2 and IFN-γ.
Xu H; Tan X; Kong Y; Huang Y; Wei Z; Ye X
J Cancer Res Ther; 2022 Apr; 18(2):532-544. PubMed ID: 35645125
[TBL] [Abstract][Full Text] [Related]
87. Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade.
Harel M; Lahav C; Jacob E; Dahan N; Sela I; Elon Y; Raveh Shoval S; Yahalom G; Kamer I; Zer A; Sharon O; Carbone DP; Dicker AP; Bar J; Shaked Y
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35718373
[TBL] [Abstract][Full Text] [Related]
88. Comments on 'Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer'.
Takada K; Takamori S
ESMO Open; 2022 Dec; 7(6):100599. PubMed ID: 36208495
[No Abstract] [Full Text] [Related]
89. Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer.
Wei F; Sasada T
Genes Immun; 2024 Feb; 25(1):89-91. PubMed ID: 38097745
[No Abstract] [Full Text] [Related]
90. Immune checkpoint inhibitor-associated panniculitis: clinicopathological features and cytokine profiles.
Hung YT; Chung WH; Huang YL; Chen CB
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e834-e837. PubMed ID: 35686625
[No Abstract] [Full Text] [Related]
91. Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment.
Tong J; Mao Y; Yang Z; Xu Q; Zheng Z; Zhang H; Wang J; Zhang S; Rong W; Zheng L
Cancer Manag Res; 2021; 13():4041-4053. PubMed ID: 34040444
[TBL] [Abstract][Full Text] [Related]
92. Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy.
Rubino R; Marini A; Roviello G; Presotto EM; Desideri I; Ciardetti I; Brugia M; Pimpinelli N; Antonuzzo L; Mini E; Livi L; Maggi M; Peri A
Endocrine; 2021 Oct; 74(1):172-179. PubMed ID: 34036513
[TBL] [Abstract][Full Text] [Related]
93. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
Horinouchi H; Nogami N; Saka H; Nishio M; Tokito T; Takahashi T; Kasahara K; Hattori Y; Ichihara E; Adachi N; Noguchi K; Souza F; Kurata T
Cancer Sci; 2021 Aug; 112(8):3255-3265. PubMed ID: 34036692
[TBL] [Abstract][Full Text] [Related]
94. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
95. Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors.
Chen YY; Wang PP; Fu Y; Li Q; Tian JF; Liu T; Lin Z; Ding ZY
J Bone Oncol; 2021 Aug; 29():100369. PubMed ID: 34036039
[TBL] [Abstract][Full Text] [Related]
96. Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer.
Chen Y; Wen S; Xia J; Du X; Wu Y; Pan B; Zhu W; Shen B
Front Immunol; 2021; 12():672271. PubMed ID: 34054853
[TBL] [Abstract][Full Text] [Related]
97. The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors.
Wang M; Zhai X; Li J; Guan J; Xu S; Li Y; Zhu H
Front Immunol; 2021; 12():670391. PubMed ID: 34367136
[TBL] [Abstract][Full Text] [Related]
98. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
99. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
Sánchez-Gastaldo A; Muñoz-Fuentes MA; Molina-Pinelo S; Alonso-García M; Boyero L; Bernabé-Caro R
Transl Lung Cancer Res; 2021 Jun; 10(6):2509-2522. PubMed ID: 34295658
[TBL] [Abstract][Full Text] [Related]
100. Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer.
Nie X; Xia L; Gao F; Liu L; Yang Y; Chen Y; Duan H; Yao Y; Chen Z; Lu S; Wang Y; Yang C
Front Mol Biosci; 2021; 8():678753. PubMed ID: 34095230
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
